Picture of Taisho Pharmaceutical Holdings Co logo

4581 — Taisho Pharmaceutical Holdings Co News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Oasis says it opposes Taisho Pharma's $5 bln management buyout

By Makiko Yamazaki
       TOKYO, Feb 12 (Reuters) - Oasis Management, a Hong
Kong-based activist fund, said it is opposed to Taisho
Pharmaceutical's  4581.T  $5 billion management buyout as it
believes the acquisition price was too low.
    The Japanese firm's founding family gained 73% of the
company in a tender offer last month for 8,620 yen per share -
in the country's largest management buyout to date. That
represented a 55% premium to Taisho's share price before the
offer was announced but was still below book value. 
    The family is seeking support for a reverse stock split in
March that would consolidate Taisho's shares - a vote it is sure
to win as it commands more than the two-thirds of vote needed to
secure approval.
    But under a so-called appraisal process, shareholders could
go to court to seek a higher price. The process is designed to
protect investors who oppose a buyout by allowing them to ask a
judge to determine the fair value of a stock.
    "We think the company should be taken away...at least (for)
11,000 yen (per share)," Seth Fischer, Oasis's founder and chief
investment officer, told an investor event organised by Monex
Group  8698.T . 
    Fischer said the stock had long underperformed prior to the
buyout, adding that Oasis has been a Taisho shareholder "for a
long period of time."
    He did not disclose the size of Oasis's stake or elaborate
on what steps Oasis might take.
    

 (Reporting by Makiko Yamazaki; Editing by Edwina Gibbs)
 ((Makiko.Yamazaki@thomsonreuters.com; +81-3-4563-2805;))

Recent news on Taisho Pharmaceutical Holdings Co

See all news